Immune drug to prevent lung transplant failure
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and on the waiting list for a double lung transplant.
- Your doctor calculates a risk score above 50% for primary graft dysfunction.
- You plan to receive basiliximab, mycophenolate, and prednisone right after transplant.
- You do not have an active chronic lung infection like Burkholderia or Mycobacterium abscessus.
- You are not having a heart transplant or another organ transplant at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called letermovir, given after a lung transplant, to see if it prevents CMV infection better than the current standard drug, valganciclovir. If you're at high risk for CMV, this trial could help protect you from this common post-transplant infection.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests a drug called emapalumab for people who have a sudden drop in lung function after a lung transplant. The drug targets a protein that may be causing the damage, and the goal is to treat this reaction safely.
This trial tests a combination of three medicines (sirolimus, ruxolitinib, and mycophenolate mofetil) to prevent graft-versus-host disease (a common complication after a stem cell transplant) in people who cannot take standard anti-rejection drugs. The goal is to find a safer alternative that still protects you from this complication.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Hear when a new Primary Graft Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.